DURHAM, N.C. — Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action...

QUEENSBURY, N.Y. — Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn,...

AMSTERDAM, the Netherlands — NorthSea Therapeutics B.V. (“NorthSea” or the “Company”), a private, late-stage clinical biotechnology company leveraging its proprietary structurally engineered fatty acids (SEFAs) platform to develop novel drugs to treat rare liver diseases, today announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency’s...